Compare Johnson & Johnson (JNJ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Novavax Inc — how do they compare? Johnson & Johnson trades at $250.89 (market cap $598.96B), while Novavax Inc trades at $7.9 (market cap $1.30B). The key difference: Johnson & Johnson is far larger — about 460.7× Novavax Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| JNJ | NVAX | |
|---|---|---|
Market Cap | $598.96B | $1.30B |
Volume | 6,156,228 | — |
Sector | Health | Health |
52-Week High | $267.24 | $11.19 |
52-Week Low | $164.36 | $6.22 |
Enterprise Value | $631.90B | $800.50M |
Dividend Yield | 2.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
